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Abstract 
Several studies have made a sub category of the symptoms of schizophrenia into five parts: positive symptoms, 
negative symptoms, cognitive symptoms, symptoms of aggressive and depressive / anxious. Some studies also 
indicate that risperidone is a preparation that has high efficacy for positive symptoms of schizophrenia and 
negative symptoms of schizophrenia also improve better than conventional antipsychotics.mThis study was an 
experimental study in the form of two-group pretest-posttest design with consecutive sampling performed 40 
schizophrenic patients who came for treatment to psychiatry inpatient and outpatient BLUD RSJ Propsu period 
March 1, 2010 - August 31, 2010. Patients with schizophrenia who met the inclusion criteria and underwent total 
PANSS positive symptoms before treatment therapy 20 samples will be treated with risperidone and 20 samples 
treated with haloperidol then were followed up every week until the fourth week of the inspection and the total 
PANSS positive symptoms. From a statistical test to test for independent samples in total PANSS score of zero 
to weeks and weeks to four PANSS total score differences were found on average to risperidone treatment group 
50.2 (SD ± 9.7) and the difference in the PANSS total score average for haloperidol treatment group of 47.4 (SD 
± 6.5), P = 0.281. No difference in total PANSS score based group intervention. From test to test for independent 
samples positive PANSS scores week to zero and week four PANSS positive score differences were found on 
average to risperidone therapy of 13.1 (SD ± 3.4) and the difference in PANSS positive scores on average for 
group therapy haloperidol was 10.5 (SD ± 1.9) P = 0.005. There are differences in symptom positive delta based 
group intervention. In this study risperidone group showed no significant differences in symptom score of the 
PANSS positive until the fourth week compared with the use of haloperidol group. 
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1. Introduction 
Schizophrenia is a collection of clinical symptoms are characterized by damage psychopathology involving 
cognition, emotion, perception and behavioral aspects and manifests in patients and affect the course of the 
disease, usually severe and prolonged.
1
 Schizophrenia is a severe mental disorder that trips include chronic 
illness,
2.3
 is generally characterized by a distorted thoughts and perceptions basic, and by affective unnatural 
(inappropriate) or blunt (blunted).
3
  
Although not yet formally recognized as part of the diagnostic criteria for schizophrenia, several studies 
made subcategories of symptoms of this disease into 5 parts: positive symptoms, negative symptoms, cognitive 
symptoms, aggressive symptoms and depressive/anxious symptoms. The positive symptoms include delusions 
positive, hallucinations, irregularities and exaggeration in language and communication, irregular 
behavior/speech, behavior catatonic and agitation.
4
 
Basic treatment of schizophrenia is antipsychotic medication to be divided into two major groups, 
namely the typical antipsychotics (dopamine receptor antagonists) and atypical antipsychotics (serotonin 
receptor antagonist dopamine).
5
 Some research suggests that risperidone is the preparation that has high efficacy 
for positive symptoms schizofrenia and improve negative symptoms schizophrenia better than conventional 
antipsychotics.
6
 
John Davis recently analyzed data collected from 5-controlled study. The results of a meta-analysis 
showed that 53% of patients who received risperidone with dose  above 6 mg daily meet criteria improvement 
than expected in  40% of patients who received conventional antipsychotic (p <0.001). Treatment with 
risperidone also provide 25% better improvement on the positive symptom and 60% better on negative 
symptoms compared with conventional antipsychotics. 
7
 
 
2. Subject and Methods 
This study was approved by the Research Ethics Committee of Medical Faculty University of Sumatera Utara. 
This study was performed in outpatient clinic and inpatient of Mental Hospital of Province of North Sumatera, 
on the regulation of Medical Faculty of University of North Sumatera, from 1 March 2010 to 31 August 2010. 
The criteria inclusion for subject were patient schizophrenic who meet the criteria PPDGJ III, ages 15-55 years 
and in acute phase. We excluded patients with schizophrenia and comorbid general medical illness or other 
psychiatric disorders, pregnant and nursing and hypersensitivity to risperidon and haloperidol. Written informed 
consent was obtained from all participants after giving a full explanation of the study protocol.   
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2.1 Assessment and Rating 
First, schizophrenic patients who met the diagnostic criteria for schizophrenia (F20) based PPDGJ I – III will be 
assessed with PANSS to assess the positive symptoms consist of delusions, thought processes chaos, 
hallucinatory behavior, rowdy anxiety, delusions of grandeur, suspicion/chase, hostility.
8
 Improvement which is 
considered the progress in therapy is the reduction in total PANSS score reached ≥ 40%. Risperidone is an 
atypical antipsychotic with a dose range of 2-8 mg/day.
9
 Haloperidol is an antipsychotic tipical butyrophenone, 
the dose range 5-20 mg/day.
9
 The acute phase is where common psychotic clear picture, for example, there are 
delusions, hallucinations, impaired thought processes and usually lasts 4-8 weeks.
10 
2.2 Statistical Analysis 
The data collected were processed and analyzed using the software  Statistical Package for Social Sciences 
(SPSS) version 15.0 with a significance level of p <0, 05.  
 
3. Result 
Forty schizophrenic patients who came to the general psychiatry clinic, ward male / female and IGD BLUD 
Psychiatric Hospital of North Sumatra province have participated in this study. The selection of the sample in 
this study defined a non-probability sampling types consecutive in time period 1 March 2010 until August 31, 
2010.  
 
Table 4.1. The sample distribution based on demographic characteristics.  
 
From table 4.1. above, it can be seen that the sample distribution by age group has the most samples are 
the age groups 25-34 of 17 samples (42.5%) and having at least a sample is the age group 45-55 for 2 samples 
(5%) , the basis of sex which has the most number of samples is the male sex of 26 samples (65%). 
  
 Table 4.2. Distribution of the sample group and risperidone therapy Haloperidol based on demographic 
characteristics.  
 
 
From table 4.2. above, can be seen in the treatment group risperidone by age group that has the most 
samples are the age groups 15-24 years and 25-34 years for each of the 8 samples (40%). And at least a sample is 
the age group 45-55 years at 1 sample (5%). In the haloperidol treatment group who has the most samples are 
25-34 years age group of 9 samples (45%) and the least amount of samples is the age group 45-55 years at 1 
sample (5%).  
In the risperidone treatment groups based on gender can be seen that with the most samples are male 
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sex of 14 samples (70%). In the treatment group who has the most heriperidol sample was male gender of the 12 
samples (60%).  
 
Table 4.3. The relationship between treatment groups and h r isperidon aloperidol on demographic 
characteristics  
 
Demographic Characteristics of Sample  Therapy    
  Risperidone  Halope
ridol  
P  
  n  %  n  %     
Age groups  
15-24  
25-34  
35-44  
45-55  
  
8  
8  
3  
1  
  
40  
40  
15  
5  
  
3  
9  
7  
1 
  
15  
45  
35  
5  
  
   
0.2
69  
  
Sex  
Male  
Female  
  
 
14  
6 
  
 
70  
30  
  
 
12  
8 
  
 
60  
40 
  
  
0.5
07  
  
 
From table 4.3. The above can be seen the relationship between treatment groups Rispe ridon and 
haloperidol on demographic characteristics. In the age group, from a statistical test by using Chi-square Test 
results P = 0.269 was found (P> 0.05). T here is no perbed aan risperidone and haloperidol group proportions by 
age group.  
Of tests on sex by using chi-square Test results P = 0.507 was found (P> 0.05). T here is no difference 
in the proportion of risperido n haloperidol treatment groups based on group sex.  
  
Table 4.4. The relationship between risperidone and haloperidol treatment groups on the characteristics 
of Weight Loss   
 
Of the test by using Independent Samples Test on body weight was found average values for risperidone 
treatment group was 22.1 (SD ± 0.6) and the average weight for haloperidol treatment group was 22.1 (SD ± 0.6 ) 
which means that the value of P = 0.941 (P> 0.05). T here is no difference in the proportion of significant 
weight in the group will receive risperidone and haloperidol.  
 
 Table 4.5. Characteristics of the PANSS total score and PANSS positive score Sunday to zero on 
risperidone and haloperidol therapy group  
PANSS  
 Therapy   
Risperidone   Haloperidol   
  n  Mean  
Standard 
deviation  
n  Mean  
Standard 
deviation  
P  
PANSS 
Total  
20  107.25  10.1  20  112.8  11.5  0,113  
PANSS 
positive  
20  30.6  4.9  20  30.6  4.8  1,000  
From the test with Independent Samples Test on the PANSS total score of the PANSS total scores were 
found on average to risperidone therapy group at 107.2 (SD ± 10.1) and PANSS total average for haloperidol 
treatment groups at 112.8 (SD ± 11 , 5), P = 0.113 (P> 0.05). T here is no difference in the total PANSS score 
weeks to zero based group intervention.  
Of test Independent Samples Test against positive PANSS scores were found positive PANSS scores on 
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average for risperidone therapy 30.6 (SD ± 4.9) and PANSS positive score average for haloperidol treatment 
groups of 30.6 (SD ± 4.8 ), P = 1,0 ( P > 0,05 ) . This shows that no significant difference was found PANSS 
scores at the first time all schizophrenic patients with positive symptoms checked each group. 
 
Table 4.6. The difference in total PANSS score and the PANSS positive score at week zero and week four 
in the group of risperidone and haloperidol therapy. 
PANSS 
 
Therapy 
Risperidone Haloperidol  
 
 
n 
Mean 
Standard 
deviation 
n Mean 
Standard 
deviation 
p 
The difference in 
total PANSS 
20 50.2 9.7 20 47.4 6.5 0.281 
 
The difference in 
PANSS positive 
20 13.1 3.4 20 10.5 1.9 0,005 
From the test with Independent Samples Test to differences in PANSS total score of zero and a week to 
four weeks in total PANSS score differences were found on average to risperidone treatment group 50.2 (SD ± 
9.7) and the difference in the PANSS total score of the average for the group amounted to 47.4 haloperidol 
therapy (SD ± 6.5), P = 0.281 ( P > 0.05). T here is no difference in the total score of the PANSS delta based 
group intervention. 
From the test with Independent Samples Test to differences in PANSS positive score week to zero and 
the fourth week of the PANSS positive score differences were found on average to risperidone treatment groups 
of 13.1 (SD ± 3.4) and the difference in PANSS positive scores on average for haloperidol treatment groups at 
10.4 (SD ± 1.9), P = 0.005 ( P <0.05). A positive delta da difference symptom based group intervention.   
  
 Table 4.7. Side effects were found after drug administration 
 
            Risperidone Haloperidol 
 
    Side effects 
n % n % 
    Present 8 50 15 75 
    Absent 12 50 5 25 
From table 4.7. above can be seen that of the 20 people who received risperidone side effects whereas 8 of 
20 people who received haloperidol side effects 15. The side effects seen in the provision of risperidone in the 
study were akathisia, tremor and headache. While the side effects seen in the purchase of haloperidol a dalah 
tremor, akathisia, dizziness, headache, and dystonia.  
 
4. Discussion 
This research is an experimental study, in the form of two group pretest-posttest design, which is the clinical 
trials double-blind in parallel with the two groups in randomization. The aim of this study to compare the effects 
of risperidone and haloperidol on positive symptoms in patients schizophrenic. 
This research group selection schizophrenic patients aged between 15-55 years as the study sample 
because according to existing literature states that 90% of patients who received treatment schizophrenic aged 
between 15-55 years. Peak attacks in men between the ages of 10-25 years and 25-35 years in women. Attack 
under 10 years old or over 60 years reported rarely. In general, women with schizophrenia have results 
(outcomes) better than men. 
4
 
Of the forty schizophrenic patients who come to the clinic for treatment of Psychiatry Outpatient and 
Inpatient Psychiatric Hospital BLUD North Sumatra during the period 1 March 2010 - August 31, 2010 the 
results of the study found that there was no difference in proportions between the two treatment groups in terms 
of age ( P = 0.269) gender ( P = 0.507), weight ( P = 0.941). 
 Measurement of total PANSS score of zero to week results found no significant difference in the two 
treatment groups ( P = 0.113), resulting from the value P > 0.05, the two groups have equal at the beginning of 
therapy prior to treatment with risperidone and haloperidol. 
Measurement of the PANSS positive score weeks to zero results found no significant difference in the 
two treatment groups (P = 1.00) so that the value of P> 0.05, the two groups have equal at the beginning of 
therapy prior to treatment with risperidone and haloperidol . 
From the test with Independet Samples Test of the total PANSS score of zero to weeks and weeks to 
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four PANSS total score differences were found on average to risperidone treatment group 50.2 (SD ± 9.7) and 
the difference in the PANSS total score of the average for the group amounted to 47.4 haloperidol therapy ( SD ± 
6.5),P = 0.281 ( P > 0.05). T here is no difference in the total score of the PANSS delta based group 
intervention. The results of this study provide the same results with the results of research conducted by KJ Vijay 
Sagar, Cr.Chandra Shekar during 6 weeks of treatment with risperidone and haloperidol, there was no 
statistically significant difference in PANSS scores in schizophrenic patients. 
9
 
From the test with Independet Samples Test of the PANSS positive score week to zero and week four 
PANSS positive score differences were found on average to risperidone therapy 13.1 (SD ± 3.4) and the 
difference in mean PANSS positive for haloperidol treatment group was 10.5 (SD ± 1.9), P = 0.005 
( P <0.05). A positive delta da difference symptom based group intervention. Based on these results it can be 
seen that a better use of risperidone therapy in schizophrenic patients compared with the use of haloperidol in 
reducing positive symptoms.The results of this study provide the same results with the results of research 
conducted by John Davis, where the results of a meta-analysis showed risperidone meet the criteria of positive 
symptom improvement is better than conventional antipsychotics (p <0.001). 
8
   
 
5. Conclusion 
From the results of a study of 40 patients with schizophrenia who came to the Clinic of Psychiatry Outpatient 
and Inpatient Psychiatric Hospital BLUD North Sumatra Province can be deduced as follows: 
1. Characteristics of the sample demograsi risperidone treatment groups by age group has the 
most sampled age group is the age group 25-34 of 17 samples (42.5%) and having at least a 
sample is the age group 45-55 for 2 samples (5 %). 
2. Demographic characteristics of the sample on haloperidol treatment groups by age group that 
has the most samples are the age groups 15-24 years and 25-34 years for each of the 8 samples 
(40%). And at least a sample is the age group 45-55 years at 1 sample (5%). 
3.  Of test Independent Samples Test against PANSS can be seen the relationship between 
treatment groups Rispiridon and haloperidol on demographic characteristics. In the age group, 
of the test by using Chi-square test P = 0.269 results found (P> 0.05). T here is no difference 
in the proportion of risperidol and haloperidol groups by age group. Of tests on sex by 
using chi-square test P = 0.507 results found significant P values> 0.05, there was no 
difference in the proportion of risperidol haloperidol groups based on gender. 
4. Of the test by using Independent Samples Test against weight found the average weight for 
risperidone treatment group was 22.1 (SD ± 0.6) and the average weight for haloperidol 
treatment group was 22.1 (SD ± 0, 6) the value of P = 0.941, (P> 0.05). T here is no difference 
in body weight in the intervention group. 
5. Of Independent Samples Test to test positive PANSS positive PANSS found on average to 
risperidone therapy 30.6 (SD ± 4.9) and the mean PANSS positive for haloperidol treatment 
groups of 30.6 (SD ± 4.8), the value P = 1.0 (P> 0.05). There is no difference in the total score 
of the PANSS delta based group intervention. 
6. From the test with indepe nt Samples Test against the PANSS positive score difference weeks 
to zero and the fourth week found differences mean PANSS positive for risperidone treatment 
groups of 13.1 (SD ± 3.4) and the difference in PANSS positive scores on average for the 
group haloperidol therapy at 10, 5 (SD ± 1.9), the value of P = 0.005 (P <0.05). A positive 
delta da difference symptom based group intervention. 
From the results of the study we suggest that: (1) use of risperidone therapy have better efficacy in 
schizophrenic patients dibandin gkan with haloperidol therapy in reducing positive symptoms; and (2) need to do 
more extensive research with larger samples to address issues with respect to effectivity of risperidon and 
haloperidol to schizophrenic patients. 
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